
Ever Supreme Bio Technology is a clinical-stage biotech company focused on developing next-generation allogeneic cell therapies for solid tumors. Its lead candidate, CAR001, combines gamma delta T cells targeting HLA-G with BiTE-mediated PD-L1 engagement to overcome two major barriers in current solid tumor treatment: tumor heterogeneity and immune evasion. With operations in Taiwan and early clinical trials underway, Ever Supreme also runs a revenue-generating CDMO platform and is expanding its pipeline to include stem cell and exosome-based therapies. Backed by a strong IP portfolio across…
Annual Revenue$50M to $100M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.